

## DAFTAR PUSTAKA

1. World Health Organization. Global Tuberculosis Report 2017. Geneva: WHO Press; 2017
2. Kementerian Kesehatan Republik Indonesia Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Petunjuk Teknis Manajemen Terpadu Pengendalian Tuberkulosis Resistan Obat. Jakarta: Kemenkes RI; 2014.
3. Kementerian Kesehatan republik Indonesia Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman Nasional Pengendalian Tuberkulosis. Jakarta: Kemenkes RI; 2014.
4. Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A systematic Review and Meta-analysis. *American Journal of Therapeutics*. 2016;23(2):521-30.
5. Reviono, Kusnanto P, Eko V, Pakiding H, Nurwidiasih D. *Multidrug Resistant Tuberculosis (MDR-TB) Tinjauan epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis*. *Majalah Kedokteran Bamdung*. 2014; 46(4): 189-96
6. Zhang Y, Wu S, Xia Y, Wang N, Zhou L, Wang J, et al. Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study. *Med Sci Monit*. 2017; 23: 2348-56.
7. Aznar. ML, Segura AR, Moreno. MM, et al. Treatment Outcomes and Adverse Events from a Standardized Multidrug-Resistant Tuberculosis

- Regimen in a Rural Setting in Angola. *The American Journal of Tropical Medicine and Hygiene*. 2019; 101(3):502 –9
8. Muñoz-Torrico M, José Caminero-Luna, Migliori GB, et al. Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. *Arch Bronconeumol*. 2017;53(5):245–50
  9. World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: WHO Press; 2014. 7-8.
  10. Trauner A, Borell S, Reither K, Gagneux S. Evolution of Drug Resistance in Tuberculosis: Recent Progress and Implications for Diagnosis and Therapy. *Drugs*. 2014; 74: 1063-1072.
  11. Gilpin C, Korobitsyn A, Weyer A. Current Tools Available for the Diagnosis of Drug-Resistant Tuberculosis. *Therapeutic Advances in Infectious Disease*. 2016; 3(6): 145-51
  12. World Health Organization. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis (MDR-TB). Geneva. WHO Press: 2008. 2-6.
  13. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. Availability of an Assay for Detecting *Mycobacterium tuberculosis*, Including Rifampicin-Resistant Strains, and Considerations for Its Use. United States: MMWR; 2013: 1-8
  14. World Health Organization. The use of molecular line probe assay for the detection of resistance to isoniazid and rifampicin: policy update. Geneva. WHO Press: 2016. 2-7.

15. Challenge TB, KNCV, Kementerian Kesehatan Republik Indonesia. Panduan Pelayanan Tuberkulosis Resistan Obat Untuk Fasilitas Pelayanan Kesehatan. Kemenkes RI: 2019.(3)
16. Kementerian Kesehatan Republik Indonesia Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Petunjuk Teknis Pengobatan Pasien TB Resistan Obat dengan Paduan Standar Jangka Pendek Di Fasyankes TB Resistan Obat. Jakarta. Kemenkes RI; 2017.
17. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia No.67 Tahun 2016 Tentang Penanggulangan Tuberculosis. Kemenkes RI; 2016
18. Jose A Caminero. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. Paris. International Union Against Tuberculosis and Lung Disease: 2013.
19. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PPJ, Chiang C-Y, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. *Trials*.2014; 15: 353.
20. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva. WHO Press: 2019.
21. World Health Organization. WHO treatment guidelines for multidrug-and rifampicin-resistant tuberculosis 2018 update. Geneva: WHO Press; 2018
22. Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar J. Risk Factor of Multidrug Resistant Tuberculosis : A Global Systematic Review and Meta Analysis. *Journal of Infection* . 2018; 77:469-78.

23. Kawatsu L, Uchimura K, Izumi K, Ohkado A, Yoshiyama T. Treatment Outcome of Multidrug-Resistant Tuberculosis in Japan- the First Cross-Sectional Study of Japan Tuberculosis Surveillance Data. *BMC Infectious Disease*. 2018; 18:1-7
24. Gualano G, Mencarini P, Musso M, Mosti S, Santangelo L, Murachelli S, et al. Putting in Harm to Cure : Drug Related Adverse Event Do Not Affect Outcome of Patients Receiving Treatment for Multidrug-Resistant Tuberculosis. Experience from Tertiary Hospital in Italy. *PlosOne*.2019:1-14.
25. Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Adverse Drug Reaction During Drug-Resistant TB Treatment in High HIV Prevalence Setting: A Systematic Review and Meta-analysis. *Journal of Antimicrobial Chemotherapy*. 2017; 72:1871-9.
26. Sagwa E, Kaija A, Teeuwisse M, Ruswa N, Musasa JP, Pal S, dkk. The Burden of adverse events during treatment of drug-resistant tuberculosis in Namibia Southern. *Med Rev*. 2012; 5(1) 6-13
27. Dela AI, Tank NKD, Singh AP, Piparva KG. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre : A four year retrospective study. *Lung India*. 2017;34 (6): 522-6.
28. Yang TW, Park HO, Jang HN, Yang JH, Kim SW, Moon SH, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea. *Medicine*. 2017; 96 (28): 1-5.
29. Bhatt CP, KC B. Side effect associated with drugs used in treatment of multi drug resistant tuberculosis and treatment related factors of multidrug resistant

- tuberculosis patients in Kathmandu valley. SAARC Journal of Tuberculosis, Lung Disease and HIV/AIDS. 2017; 14(1): 1-6
30. Merid MW, Gezie LD, Kassa GM, Muluneh AG, Akalu TY, Yenit MK. Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia : a retrospective cohort study. BMC Infectious Disease. 2019; 19(286): 1-12.
31. Bastos ML, Lan Z, Menzies D. An updates systematic review and meta-analysis for tretament of multidrug-resistant tuberculosis. ERS. 2017;49:1-15.
32. Shinde MP, Halaswadekar NR, Ramanand SJ, Pore SM, Ramanand JB, Patil PT, et al. A study of adverse drug reactions in patients receiving treatment for multi-drug resistant tuberculosis. International Journal of Basic and Clinical Pharmacology. 2017;6(2): 354-8.
33. Rahmawati I, Isbaniah F, Agustin H, Sarikencana RE. The Prevalence of Ototoxicity in Drug Resistance Tuberculosis Patients and the Associated Factors at Persahabatan General Central Hospital. Jurnal Respirologi Indonesia. 2019; 39(3):180-95.
34. Pradipta J, Soepandi PZ, Burhan E, Isbaniyah F, Agustin H, Handayani D, et al. Adverse Reactions Among Patients Being Treated with Shorter Multi-Drug Resistant Tuberculosis Regimen at Persahabatan Hospital, Indonesia. Respirology. 2018; 23 (2): 72-3
35. Ahmad N, Javaid A, Sulaiman SA, Afridi AK, Zainab Z, Khan AH. Occurrence, Management, and risk factors for adverse drug reactions in

Multidrug Resistant Tuberculosis patients. American Journal of Therapeutic. 2016:1-8.

36. Lee SS, Lee CM, Kim TH, Lee JM, Kim HJ, Ha CY, et al. Frequency and risk factors of drug induced liver injury during treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis Lung Disease. 2015; 20(6): 800-5.

37. Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripc onoka V, Kramer S, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis. 2010; 14(3): 275-81.

